ArticleFrontiers in oncology2025
Stage-specific and regional trends in prostate cancer incidence in Kazakhstan, 2005-2024.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fear of Cancer Progression as a Psychological Component of Cancer Rehabilitation in Men Treated for Reproductive System Malignancies: A Multi-Regional Cross-Sectional Study in Kazakhstan.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Twenty years of age-standardized prostate cancer mortality in Kazakhstan (2005-2024): joinpoint model and geographical hot spot and cold spot analysis.BMC public health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is a leading malignancy among men globally and continues to be a growing concern in Kazakhstan, where evidence regarding its long-term epidemiological trends is limited. Objectives: This study seeks to assess national and regional trends in prostate cancer incidence, stage distribution, and morphological verification in Kazakhstan from 2005 to 2024. Methods: A nationwide observational study utilizing registry data from the Unified Nationwide Electronic Health System was performed. Incident cases (ICD-10 code C61) were examined according to age, geographical region, and stage at diagnosis. The incidence rates were adjusted to the WHO World Standard Population (2000-2025) by age. Joinpoint regression was used to look at temporal trends, and it showed the annual percent change (APC) and the average annual percent change (AAPC) with 95% confidence intervals. Results: From 2005-2024, 21,756 prostate cancer cases were recorded, with a mean age at diagnosis of 69.8 years. The age-standardized incidence rate (ASR) increased from 11.9 to 20.7 per 100,000 men (APC = +2.6%, p = 0.002). Four distinct periods were identified: an early decline (2005-2008), a sharp rise (2008-2016), a downturn (2016-2020), and a renewed increase (2020-2024). Age-specific incidence was negligible below 50 years, peaking at 75-79 years (228.6 per 100,000). Regional analyses revealed heterogeneous trends: monotonic increases in Atyrau, Aktobe, and Almaty (region), contrasted by boom-dip-rebound profiles in Karaganda, Pavlodar, and Almaty City. The proportion of early-stage (I-II) cases rose from 32.8% to 56.9%, while stage III declined from 49.7% to 22.9%; stage IV increased slightly (17.3% → 20.2%). Morphological verification improved nationally (mean ≈ 92%) and plateaued after 2015. Conclusions: Kazakhstan shows an increase in prostate cancer cases, with more cases being diagnosed at an earlier stage but still a lot of cases being diagnosed at a later stage. This is probably due to the PSA screening program from 2013 to 2017, changes in policy since then, and problems with diagnosis during the pandemic. To get better results, we need to improve early detection, timely biopsy pathways, and connections to mortality and survival data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.